VEA
TEVA icon

Virtus ETF Advisers’s Teva Pharmaceuticals TEVA Stock Holding History

Virtus ETF Advisers’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-353
Closed -$3K – 404
2021
Q2 		$3K Buy
+353
New +$3.74K ﹤0.01% 399

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Virtus ETF Advisers's TEVA Position: Q3 2021 in Review

Virtus ETF Advisers sold out of Teva Pharmaceuticals (TEVA) in Q3 2021, closing a stake of 353 shares — an estimated $3K sold.

Virtus ETF Advisers first reported a position in TEVA in Q2 2021 and held it in 1 quarter. The position peaked at $3K in Q2 2021. 429 funds tracked by Wall St. Rank hold TEVA as of Q3 2021.

  • Virtus ETF Advisers reported no remaining Teva Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Virtus ETF Advisers sold 353 Teva Pharmaceuticals shares in Q3 2021, an estimated $3K.
  • Virtus ETF Advisers first reported a position in Teva Pharmaceuticals in Q2 2021 and held it in 1 quarter.
  • Virtus ETF Advisers's Teva Pharmaceuticals position peaked at $3K in Q2 2021.
  • 429 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2021.

Based on Virtus ETF Advisers's 13F filing for Q3 2021, filed 15 Nov 2021.